Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global $48 Billion Pediatric Vaccine Market 2011-2017 & 2018-2024 with GlaxoSmithKline, Merck, Sanofi, and Pfizer Dominating

Research and Markets
Posted on: 13 Dec 18
Global $48 Billion Pediatric Vaccine Market 2011-2017 & 2018-2024 with GlaxoSmithKline, Merck, Sanofi, and Pfizer Dominating

PR Newswire

DUBLIN, Dec 13, 2018

DUBLIN, Dec 13, 2018 /PRNewswire/ --

The "Pediatric Vaccine Market, Global Forecast Infants Vaccinated, Vaccines Administered, Immunization, By Disease (Influenza, MMR, Pneumonia, Meningitis, Hepatitis, Tap, Hib, Polio, etc) & Companies" report has been added to ResearchAndMarkets.com's offering.

Pediatric Vaccine Market is projected to exceed US$ 48 Billion by the year 2024

Increasing government and non-government funding for the development of new vaccines, along with raising awareness about the benefits of vaccination, is certainly expected to positively drive the market growth in the coming years. In order to cut the healthcare expenses, governments have been making continuous efforts to reduce the cost of patient immunization through various vaccination programs funded by government or non-government health authorities. For example; several countries have included Children Vaccination Programs, which offers vaccines to children who lack health insurance or one who cannot afford the cost of vaccination.

Growing prevalence of chronic diseases is another major market driver, driving the market of infant (pediatric) vaccines. The immune system is not fully developed in infants, hence they are at a higher risk of contracting severe diseases and so, vaccination plays a significant role in their prevention.

According to WHO; effective immunization activities have had a major impact on reducing measles deaths. It is found that measles vaccination prevented an estimated 20.4 million deaths across the globe. Global measles deaths have decreased by 84% from an estimated 550,100 in 2000 to 89,780 in 2016.

Nearly 650 Million Vaccines Doses will be administered in Pediatrics (Infants) by the year 2024

It is estimated that by the year 2024, the doses of vaccines administered will reach nearly 650 Million. The number of vaccine doses is expected to grow considerably during the forecast period due to growing awareness among the parents about the benefits of vaccines and also the developing countries around the world that now have included a number of vaccines to their national immunization programme as per WHO recommendations, which indeed will drive the pediatric vaccine market in recent years.

Company Analysis:

GlaxoSmithKline, Merck, Sanofi, and Pfizer are some of the top companies that deal efficiently with vaccine business globally. These companies have been studied thoroughly in the report.

Key Topics Covered:

1. Research Findings

2. Pediatric (Infant) Vaccines Market (2011 - 2024)

3. Market & Numbers Share - Pediatric Vaccines
3.1 Pediatric Vaccine Market Share
3.2 Pediatric Vaccinated Population Share
3.3 Pediatric Doses of Vaccines Administered Share
3.4 Vaccine Companies Market Share

4. Pediatric Vaccinated Numbers

5. Pediatric Doses of Vaccines Administered

6. Disease wise - Pediatric (Infants) Vaccines Market (2011 - 2024)
6.1 Influenza
6.2 MMR (Measles, Mumps, and Rubella Vaccine)
6.3 Pneumococcal
6.4 Meningococcal
6.5 Hepatitis
6.6 DTaP
6.7 Haemophilus Influenzae Type B (HIB)
6.8 Combos (Combination)
6.9 Polio
6.10 Rotavirus
6.11 Varicella

7. Disease wise - Numbers of Vaccinated Pediatric (Infants) (2011 - 2024)
7.1 Influenza
7.2 MMR
7.3 Pneumococcal
7.4 Meningococcal
7.5 Hepatitis
7.6 DTaP
7.7 Hib (Haemophilus Influenzae Type B)
7.8 Combos (Combination Vaccines)
7.9 Polio
7.10 Rotavirus
7.11 Varicella

8. Disease wise - Doses of Vaccines Administered in Pediatric (Infants) (2011 - 2024)
8.1 Influenza
8.2 MMR
8.3 Pneumococcal
8.4 Meningococcal
8.5 Hepatitis
8.6 DTaP
8.7 Hib (Haemophilus Influenzae Type B)
8.8 Polio
8.9 Rotavirus
8.10 Varicella

9. Disease wise - Immunization Profile
9.1 Immunization Coverage (%) in Infants
9.2 Global Immunization Profile
9.3 Regional Immunization Profile
9.3.1 Measles - Number of Reported Cases
9.3.2 Mumps - Number of Reported Cases
9.3.3 Rubella - Number of Reported Cases
9.3.4 Rubella (CRS) - Number of Reported Cases
9.3.5 Diphtheria - Number of Reported Cases
9.3.6 Tetanus (Neonatal) - Number of Reported Cases
9.3.7 Tetanus (Total) - Number of Reported Cases
9.3.8 Pertussis - Number of Reported Cases
9.3.9 Polio - Number of Reported Cases
9.3.10 Yellow Fever - Number of Reported Cases
9.3.11 Japanese encephalitis - Number of Reported Cases

10. Vaccines Key Players Sales (2011 - 2024)
10.1 GlaxoSmithKline, plc.'s Vaccines Sales
10.2 Merck & Co. Vaccines Sales
10.3 Sanofi Pasteur's Vaccines Sales
10.4 Pfizer, Inc.'s Vaccines Sales
10.5 Global - Other Companies Vaccines Sales

11. Vaccines - Products and Pipeline
11.1 GSK Vaccine Product Pipeline
11.2 Merck Vaccine Product Pipeline
11.3 Sanofi Vaccine Product Pipeline
11.4 Pfizer Vaccine Product Pipeline

12. Top Mergers and Acquisitions in the Vaccine Industry

13. Vaccines and Regulator's Interventions
13.1 Making and Meeting Standards of Quality and Safety
13.2 Vaccine Funding

14. Vaccine Market Drivers
14.1 Inclusion in National Immunization Schedule
14.2 Growing Immunization Coverage for HPV Vaccines
14.3 Increase in Prevalence of Infectious Diseases
14.4 Global Immunization Vision and Strategy (GIVS)
14.5 GAVI Model Fuelling Vaccine Manufacturers
14.5.1 The Partnership Model
14.5.2 The Business Model
14.6 Increasing Vaccine Availability in United States
14.7 The Vaccine Safety Data link Project
14.8 The Vaccine Injury Compensation Program
14.9 Transforming of Vaccine Technologies
14.10 Global Vaccine Action Plan by WHO (2011 - 2020)
14.11 Continuous Focus on Effective Communication Strategies

15. Vaccines Market Challenges
15.1 Hurdles to Optimal use of Licensed Vaccines
15.1.1 Technical Obstacles
15.1.2 Economic Obstacles
15.1.3 Cultural Obstacles
15.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
15.2.1 Legal Obstacles
15.2.2 General Technical Barriers
15.2.3 Economic Barriers
15.2.4 Regulatory Barriers
15.3 Shortening the Timeline for Vaccine Development
15.4 Refusal/Resistance to Vaccination
15.4.1 Vaccine Adverse Event Reporting System
15.5 Vaccine Shortages and Delays
15.6 Obstacles in Vaccine Research & Development
15.7 Barriers to New Entrants in the Vaccines Market

Companies Mentioned

  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sanofi

For more information about this report visit https://www.researchandmarkets.com/research/j62hzw/global_48?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

View original content:http://www.prnewswire.com/news-releases/global-48-billion-pediatric-vaccine-market-2011-2017--2018-2024-with-glaxosmithkline-merck-sanofi-and-pfizer-dominating-300765017.html

SOURCE Research and Markets

PR Newswire
www.prnewswire.com

Last updated on: 13/12/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.